Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EBT (2023 - 2025)

Zenas BioPharma has reported EBT over the past 3 years, most recently at $148.2 million for Q4 2025.

  • Quarterly results put EBT at $148.2 million for Q4 2025, up 362.1% from a year ago — trailing twelve months through Dec 2025 was $10.7 million (up 106.65% YoY), and the annual figure for FY2025 was $10.7 million, up 106.64%.
  • EBT for Q4 2025 was $148.2 million at Zenas BioPharma, up from -$51.5 million in the prior quarter.
  • Over the last five years, EBT for ZBIO hit a ceiling of $148.2 million in Q4 2025 and a floor of -$56.5 million in Q4 2024.
  • Median EBT over the past 3 years was -$35.9 million (2024), compared with a mean of -$13.9 million.
  • Biggest five-year swings in EBT: tumbled 208.37% in 2024 and later surged 362.1% in 2025.
  • Zenas BioPharma's EBT stood at -$24.8 million in 2023, then plummeted by 128.15% to -$56.5 million in 2024, then surged by 362.1% to $148.2 million in 2025.
  • The last three reported values for EBT were $148.2 million (Q4 2025), -$51.5 million (Q3 2025), and -$52.2 million (Q2 2025) per Business Quant data.